Searched for
PHARMACEUTICAL REGULATION MAHARASHTRA
These large- and mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos have upside potential of up to 25%, according to analystsTalk of tariffs, especially steep ones, makes the market nervous. Which is exactly why the next few trading sessions are critical, and why ...18 Sep, 2026, 01.39 PM IST- Hospitals seek new pricing rules as Maharashtra FDA flags high markupsThe healthcare industry seeks a differentiated framework for medical device pricing reviews. Hospitals incur significant costs beyond procu...17 Sep, 2026, 11.14 AM IST
- Chemical sector: Although long, there is a way around China trouble; combine 20 stocks to get your portfolio’s chemistry rightFor the chemicals sector, it all depends on a transformation that is still unfolding and will take years to play out. Backward-integration ...17 Aug, 2026, 11.07 AM IST
- 'You are using sword to kill mosquito': Bombay HC tells Tukaram Mundhe-led FDA to use power judiciouslyThe Bombay High Court has told the Tukaram Mundhe-led Maharashtra FDA to use its powers judiciously after Cadila Pharmaceuticals challenged...13 Aug, 2026, 10.07 AM IST
- Sun will require HC nod for Semaglutide tablet launchThe Delhi High Court has directed Sun Pharma Laboratories to seek its approval before launching semaglutide tablets, following Novo Nordisk...12 Aug, 2026, 12.47 AM IST
- Bombay HC warns Maharashtra FDA for ‘sword to kill mosquito’ approach as Cadila challenges drug banThe Bombay High Court criticized the Maharashtra FDA for its drastic actions against companies. The court directed the regulator to grant h...11 Aug, 2026, 09.22 PM IST
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...10 Aug, 2026, 11.10 AM IST
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsA word of caution for all those who have exposure to mid cap stocks or are planning to increase it. Just keep one thing in mind: If there i...06 Aug, 2026, 01.04 PM IST
- Saudi Aramco supplier HD Fire plans to launch IPO in OctoberFire protection systems manufacturer HD Fire Protect is planning to launch its IPO in October through an offer for sale of 2.6 crore shares...04 Aug, 2026, 02.09 PM IST
- Maharashtra FDA trains guns on overpriced drugsMaharashtra FDA plans to approach the NPPA regarding exorbitant drug prices. The agency is examining data and will take action against unet...31 Jul, 2026, 01.42 AM IST
- Over 160 drug samples found sub-standard in DecemberA recent inspection by India's drug regulator has revealed a troubling statistic: 167 medication samples were classified as not of standard...22 Jan, 2026, 01.03 AM IST
- Authorities cancel licences of several drug companies for lapsesRegulators had inspected dozens of drug manufacturing units in Himachal Pradesh, Uttarakhand, Haryana, Madhya Pradesh and Maharashtra, foll...21 Apr, 2023, 07.10 PM IST
- Maharashtra recalls Maiden Pharmaceuticals products, to inspect units making liquid oralsThe state regulator has ordered a complete examination of the manufacturing processes and the excipients or solvents that are used in cough...13 Oct, 2022, 12.17 AM IST
- Drug regulator directs J&J to pay Rs 74 lakhs to a patientAfter nearly a year of setting up a committee under Dr Arun Kumar Agarwal, a report was submitted to the health ministry with its final rec...11 Mar, 2019, 08.45 AM IST
- Wanbury export issue shows regulator miscommunicationThe Maharashtra Food and Drug Administration’s finding that Wanbury shipped to four countries batches of metformin hydrochloride produced b...25 Oct, 2016, 12.42 AM IST
- Maharashtra FDA writes to National Pharmaceutical Pricing Authority to regulate prices of stentsThe Maharashtra FDA has found that the companies that import cardiac stents inflate the Maximum Retail Price (MRP) of the stents during imp...19 May, 2015, 09.54 PM IST
- Pharma cos may face penalties for overpricingDrugmakers, such as Dr Reddy’s Laboratories, Wyeth, GlaxoSmithKline (GSK) Pharmaceuticals and Alkem Laboratories, may now have to face stat...24 Feb, 2009, 02.19 AM IST
Load More
